IP8 Depression Therapeutics Practice Test

These questions are part of the practice quiz. Start practicing

• What two questions are asked in the PHQ-2 screening tool?
• Escitalopram is the S-enantiomer of which antidepressant?
• Which monitoring/counseling point is noted for duloxetine?
• Which augmentation agent is not a great choice when anxiety symptoms coexist?
• Why are MAOIs not commonly used to treat depression?
• Levomilnacipran is described as a stronger inhibitor of norepinephrine reuptake but with what comparative efficacy?
• Which antidepressants are impacted by CYP2D6?
• Which class is identified as the most effective adjunct to SSRI in difficult-to-treat depression?
• Why are TCAs not commonly used to treat depression?
• In melancholic features, which treatment approaches might be considered?
• Which condition represents a contraindication to using bupropion?
• Which antidepressant is first-line for children aged eight years and older?
• When switching antidepressants, how long does a typical cross-taper last?
• What is the route of zuranolone administration?
• What is the preferred form for using thyroid hormone as a depression augmentation?
• Describe vilazodone's mechanism and one key tolerability issue.
• In clinical practice, augmentation of SSRI therapy in treatment-resistant depression commonly uses which drug class?
• Esketamine is administered under which supervision?
• Desvenlafaxine is an active metabolite of which antidepressant?
• Which option is a characteristic feature of serotonin syndrome?
• Which option is considered a first-line antidepressant?
• What is the mechanism of action of bupropion and what major contraindication should be considered?
• Name two augmentation strategies used in TRD and describe when each is considered.
• In difficult-to-treat depression, augmentation of SSRI with which class is commonly recommended based on available evidence?
• Repetitive transcranial magnetic stimulation (rTMS) is best described as what, and when is it typically used in depression?
• For a partial response (20-50% improvement) after a 4-8 week trial of first-line antidepressant therapy, what is the recommended next step?
• In lactation, if a patient is doing well on antidepressant, what is recommended?
• What is serotonin syndrome and how is it managed?
• What is the typical onset time for antidepressants to show clinical effect, and what should be done if there is no improvement after a reasonable trial?
• In depression treatment goals, how is remission defined?
• Which augmentation strategy to SSRI has the strongest evidence for improving outcomes in treatment-resistant depression?
• What is the current understanding of the relationship between the HPA axis, inflammation, and depression treatments?
• In pediatric patients, which therapy should be used in combination with antidepressants to maximize effectiveness?
• Both citalopram and escitalopram require ECG monitoring for QTc prolongation.
• Which statement best describes a common management approach for antidepressant-associated sexual dysfunction?
• Which statement about TSH targets in thyroid augmentation is true?
• What is the recommended duration to consider stopping thyroid augmentation after remission?
• Which adverse effect is of concern with SSRIs/SNRIs in older adults due to SIADH?
• Which augmentation strategy has the strongest evidence for efficacy in difficult-to-treat depression?
• Which drug class is often used as augmentation to SSRI in difficult-to-treat depression, with evidence supporting its efficacy?
• After intranasal esketamine administration for treatment-resistant depression, what is a key safety monitoring requirement?
• Which augmentation agent is noted to potentially minimize sexual adverse effects from SSRIs/SNRIs?
• Which of the following is NOT one of the three options for switching antidepressants?
• When selecting antidepressants for elderly patients, which considerations are important?
• Which antidepressant class is most associated with sexual dysfunction as a common adverse effect?
• Which augmentation has the strongest evidence for efficacy when adding to SSRI in difficult-to-treat depression?
• Which pair of antidepressants would most benefit from cross-tapering?
• Which atypical antipsychotic is commonly used as an adjunct to mood stabilizers in bipolar depression?
• Which antidepressant is listed among the least weight-neutral medications?
• What is the general approach to treating bipolar depression differently than unipolar depression pharmacologically?
• Which antidepressant is less preferred in pregnancy due to increased risk of fetal heart defects with first-trimester exposures?
• Which antidepressant has the highest incidence of sexual dysfunction?
• Which of the following is a commonly observed adverse effect of second-generation antipsychotics?
• Which antidepressants have the lowest incidences of sexual dysfunction?
• Which drug class is shown to be most effective when added to an SSRI for difficult-to-treat depression?
• What is the rapid-acting antidepressant mechanism of ketamine and what is a major safety consideration?
• What is the most common monitoring finding with zuranolone?
• If there is a response (>50% symptom improvement) after 4-8 weeks of first-line antidepressant therapy, what is the recommended next step?
• Which of the following is an augmentation agent mentioned for partial response if not already on board?
• Which statement is true regarding CYP2C19 and antidepressants?
• What are the primary pharmacologic effects of mirtazapine and a common side effect profile?
• What symptoms might a patient notice after 1-2 weeks of depression therapy?
• Which product is the combination of olanzapine and fluoxetine used for augmentation?
• What constitutes an adequate antidepressant trial in terms of duration and dosing?
• How might major depressive disorder with anxious distress versus melancholic features differ, and how might this influence treatment choices?
• How long do the effects of sexual dysfunction last with antidepressants?
• Which antidepressant class is often associated with hyponatremia risk in elderly patients, necessitating monitoring?
• If there is only a partial response after an adequate antidepressant trial, what is the recommended next step?
• What is a practical consideration for medication adherence in depression management?
• Which antidepressant is listed as a first-line option for treating depression in pregnant treatment-naive patients?
• For depression with coexisting neuropathic or musculoskeletal pain, which statement best describes duloxetine or venlafaxine?
• Which option is NOT listed as a common ADR of antidepressants?
• Which class includes aripiprazole and brexpiprazole used in augmentation?
• What is a key limitation of the monoamine hypothesis in explaining depression?
• If the patient is an ultra-rapid metabolizer, what is recommended?
• What is associated with 50 to 75% of difficult-to-treat depression cases?
• Which statement is true regarding CYP2D6 and antidepressants?
• In which age group is suicide risk highest after starting an antidepressant?
• What is the most common side effect of vortioxetine (Trintellix)?
• In lactation, which management aligns with the rule of not switching if doing well?
• In paroxetine, which counseling point is emphasized?
• Which class of antidepressants is associated with a greater risk of hyponatremia in older adults on diuretics?
• Which statement describes esketamine administration safety?
• What screening tool is commonly used to assess depressive symptom severity in primary care and research, and provide an example of scoring?
• Which medication is a first-line antidepressant option?
• Which antidepressant is commonly used to aid sleep in depression and has a rare risk of priapism?
• What are the major pharmacologic characteristics of tricyclic antidepressants (TCAs) and why are they used with caution?
• Which statement best describes considerations for thyroid augmentation?
• Which augmentation agent is rarely used for unipolar depression?
• Which classes have largely fallen out of favor to treat depression?
• Serotonin syndrome is most likely to occur within how many hours after adding a serotonergic medication or increasing its dose?
• In antidepressant pharmacotherapy, what is the impact of pharmacokinetic interactions such as fluoxetine's potent CYP2D6 inhibition?
• How can pharmacogenomics influence antidepressant dosing and response, particularly with CYP2D6?
• What tool is commonly used to assess suicidal risk and how is it used?
• Zuranolone is indicated for postpartum depression starting when?
• Which statement accurately describes when ECT or rTMS should be considered in treatment-resistant depression?
• Which strategy is recommended for antidepressant-induced sexual dysfunction?
• Augmentation to SSRI for resistant depression frequently involves adding which class?
• Approximately what number of hours do about 60% of serotonin syndrome cases present after a medication change?
• Which atypical antipsychotic is commonly used as an augmentation strategy in TRD?
• Why is it important to monitor for mania or hypomania when treating depression with antidepressants?
• Among augmentation strategies for SSRI-treated depression, which is least supported by evidence?
• What are the common side effects to monitor for SSRIs in older adults, and how can risk be mitigated?
• Which group shows decreased suicide risk on antidepressants?
• What is electroconvulsive therapy (ECT)?
• What is the purpose and typical duration of the maintenance phase?
• What are common discontinuation (withdrawal) symptoms when stopping an SSRI after prolonged use?
• When selecting antidepressants for patients with cardiovascular disease, which considerations are most relevant?
• Provide example dosing ranges for two commonly used SSRIs.
• What is the standard starting approach when initiating SSRI therapy and how is titration typically conducted?
• Esketamine is marketed under which brand name?
• Which medication is considered a classic mood stabilizer used in bipolar disorder?
• Lamotrigine carries a safety concern that requires monitoring during initiation. Which is the key risk?
• Which agent is described as a first-line add-on for augmentation in depression treatment?
• How does vortioxetine's mechanism differ from typical SSRIs and what potential cognitive effect is noted?
• What is the current consensus on adjunct anti-inflammatory therapies for depression?
• What factor is associated with 25 to 50% of difficult-to-treat depression cases?
• How many ECT sessions are typically given initially?
• Which antidepressants are impacted by CYP2C19?
• Which effect is commonly associated with mirtazapine?
• What is the primary mechanism of action of selective serotonin reuptake inhibitors (SSRIs) in treating depression?
• Which statement about lithium as an augmentation in unipolar depression is true?
• Which non-pharmacologic option involves stimulating the brain with magnetic fields?
• Which antidepressant is noted for potential cognitive benefits due to multimodal serotonin modulation?
• Which class of medications is supported by evidence as an augmentation to SSRI for difficult-to-treat depression?
• Which drug is identified as the most popular agent for depression augmentation?
• Which of the following is NOT a symptom of antidepressant withdrawal syndrome?
• Which of the following is not a DSM-5 symptom criterion for major depressive disorder?
• The minimum duration for depressive symptoms to meet DSM-5 criteria is how long?
• What is the typical role of lamotrigine in depressive disorders?
• Which age group shows the highest suicide risk after starting an antidepressant?
• Which antidepressants are commonly considered safer choices during breastfeeding?
• Which statement best describes augmentation strategies for treatment-resistant depression?
• For pediatric antidepressant follow-up, how often should follow-up occur during the first four weeks after starting an antidepressant?
• Which antidepressant is commonly approved for pediatric depression?
• Escitalopram is the S-enantiomer of which antidepressant?
• Fluvoxamine is FDA approved primarily for which condition?
• Which of the following is an augmentation option for partial response to first-line antidepressant therapy?
• Serotonin syndrome is most likely to occur in which scenario?
• Which sleep-related symptom is included in DSM-5 criteria for major depressive disorder?
• What is the ultimate goal for treatment of depression?
• Which scenario carries an increased risk for serotonin syndrome?
• Which phase is primarily focused on preventing future depressive episodes?
• How is treatment-resistant depression (TRD) defined in pharmacotherapy?
• Which statement about psilocybin is accurate in the current research context?
• After 3-4 weeks of depression therapy, which symptom improvement is commonly observed?
• Which nonpharmacologic treatment is considered for treatment-resistant depression in addition to pharmacotherapy?
• Venlafaxine has SNRI activity at what daily dose?
• In pharmacogenetic guidance, what is recommended for ultra-rapid metabolizers compared to poor metabolizers?
• Which agent is indicated for18-65 year olds with treatment-resistant depression after failure of at least two antidepressants?
• What is a key consideration when treating pediatric or adolescent depression with antidepressants?
• What are the common adverse drug reactions (ADRs) of antidepressants?
• How do the HPA axis and inflammatory processes relate to depression treatment considerations?
• In bipolar depression, which mood stabilizer is commonly used to prevent depressive episodes?
• What is the first-line treatment option for pregnant treatment-naive patients?
• Which statement best describes the role of psychotherapy in pediatric depression treatment when combined with pharmacotherapy?
• What is a common pharmacologic strategy to address sleep disturbance in depression?
• What is a common gastrointestinal side effect of sertraline?
• Which antidepressant is characterized by alpha2-adrenergic antagonism leading to increased norepinephrine and serotonin release, and commonly causes sedation and weight gain?
• What is the role of sleep deprivation therapy in depression management?
• What is the dosing for zuranolone?
• Which antidepressant class is associated with potential weight loss and may be preferred in overweight patients?
• What dietary interaction is critical with MAOIs?
• In treatment-resistant depression, what pharmacologic strategy is commonly pursued after two adequate antidepressant trials fail?
• How do serotonin-norepinephrine reuptake inhibitors (SNRIs) differ from SSRIs, and what are common SNRI examples?
• Which statement best describes first-line antidepressants?
• Which therapy is used to address antidepressant-induced sexual dysfunction by restoring erectile function when appropriate?
• Which treatment is typically reserved for refractory cases of depression?
• Which pharmacologic strategy is supported by evidence as an augmentation to SSRI in difficult-to-treat depression?
• How is cross-taper performed when switching antidepressants?
• What is the next treatment option after suboptimal response (<20% symptom improvement) or intolerance following 4-8 weeks of first-line antidepressant therapy?
• What is the primary purpose of lithium augmentation in TRD?
• When monitoring elderly patients on SSRIs or SNRIs, what parameter should be checked regularly?
• Which of the following is a non-pharmacologic treatment modality for depression?
• Which of the following describes adverse effects commonly seen with SSRIs and SNRIs, and which one is more SNRI-specific at higher doses?
• In depression treatment goals, what defines a 'response'?
• Which adverse effect is noted to be more common with vortioxetine compared with other SSRIs?
• Which counseling point is important for vilazodone administration?
• What is the typical trade-off when using second-generation antipsychotics as augmentation in depression?
• If the patient is a poor metabolizer, what is recommended?
• What is the recommended duration of therapy after remission for a first depressive episode?
• What defines the acute phase of treatment and its typical duration?
• Which statement is NOT listed as a consideration when prescribing antidepressants to older adults?
• What is a last-resort treatment option for treatment-resistant depression when pharmacologic strategies have been unsuccessful?
• After the initial four weeks, how often should follow-up occur for the next month?
• Which statement best describes DSM-5 criteria for depressive disorders?
• In the context of rTMS, where is the stimulation typically targeted?
• Which statement describes a dose-related effect of mirtazapine?
• How is postpartum depression addressed pharmacologically in the context of breastfeeding safety?
• Indefinite continuation of therapy for recurrent depression should be considered in which scenario?
• What is a potential advantage of esketamine for treatment-resistant depression?
• A key counseling point for fluoxetine is to avoid use in which condition due to its long half-life?
• In older adults, hyponatremia risk with SSRIs is greater particularly in which group?
• Which medication class is used specifically to address antidepressant-induced sexual dysfunction in male patients?
• Levomilnacipran is best described as which of the following?
• Desvenlafaxine is the active metabolite of venlafaxine
• Which antidepressant is often preferred during pregnancy and why, and which is generally avoided due to teratogenic risk?
• What is referred to as 'California rocket fuel' in depression augmentation?
• Which is a second-generation antipsychotic commonly used for depression augmentation?
• Which antidepressant has the highest incidence of sexual dysfunction?
• According to DSM-5 criteria for major depressive disorder, how many symptoms must be present during a 2-week period, and what is required about mood or interest?
• What PHQ-2 score prompts proceeding to the PHQ-9?
• Which pharmacologic class is commonly used as augmentation to SSRI therapy in difficult-to-treat depression?
• Based on PHQ-9 scoring, when is pharmacotherapy indicated?
• After 4-8 weeks of depression therapy, what outcome is typically expected?
• How does combining pharmacotherapy with psychotherapy affect outcomes in depression?
• If a pregnant patient is on an antidepressant and is doing well, what should be done?
• Which drug class is most commonly used to augment SSRI therapy in treatment-resistant depression?
• What is a common risk associated with electroconvulsive therapy (ECT) in depression treatment?
• What dietary and drug interactions are characteristic of monoamine oxidase inhibitors (MAOIs), and what is a key risk?
• Which antidepressant is primarily known for causing sedation and weight gain with fewer sexual side effects?
• Which antidepressant has NO detectable serum concentration in breastfed infants?
• How should psychotherapy be integrated with pharmacotherapy in depression?
• Which statement about relative infant doses of SSRIs and SNRIs in breast milk is accurate?
• Which antidepressant class has serious interactions with sympathomimetics and serotonergic drugs and requires dietary restrictions to avoid hypertensive crisis?
• After the two months, what is the recommended follow-up interval?
• What warning must be monitored when treating children with antidepressants?
• In patients with treatment-resistant depression, augmentation of an SSRI with which drug class has the strongest evidence of efficacy?
• Which statement best describes a potential effect of bupropion as an antidepressant?
• Which medication requires taking with food to ensure absorption?
• Which of the following is a notable monitoring concern with venlafaxine?
• What monitoring is recommended for citalopram?
• When is washout appropriate when switching antidepressants?
• What is a key safety requirement after an esketamine dose?